ICON9 Trial
An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Existing samples:
- Malignant tumor of ovary (disorder)
Contact Information
- Email:
- ctc.icon9@ucl.ac.uk
- Address:
-
Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2025 | N/A | N/A | N/A | N/A | N/A | N/A |